Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2011 3
2012 1
2014 3
2015 2
2016 8
2017 14
2018 18
2019 11
2020 15
2021 21
2022 19
2023 22
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Results by year

Filters applied: . Clear all
Page 1
CNS tumors with PLAGL1-fusion: beyond ZFTA and YAP1 in the genetic spectrum of supratentorial ependymomas.
Tauziède-Espariat A, Nicaise Y, Sievers P, Sahm F, von Deimling A, Guillemot D, Pierron G, Duchesne M, Edjlali M, Dangouloff-Ros V, Boddaert N, Roux A, Dezamis E, Hasty L, Lhermitte B, Hirsch E, Hirsch MPV, Ardellier FD, Karnoub MA, Csanyi M, Maurage CA, Mokhtari K, Bielle F, Rigau V, Roujeau T, Abad M, Klein S, Bernier M, Horodyckid C, Adam C, Brandal P, Niehusmann P, Vannod-Michel Q, Provost C, de Champfleur NM, Nichelli L, Métais A, Mariet C, Chrétien F, Blauwblomme T, Beccaria K, Pallud J, Puget S, Uro-Coste E, Varlet P; RENOCLIP-LOC. Tauziède-Espariat A, et al. Among authors: bielle f. Acta Neuropathol Commun. 2024 Apr 5;12(1):55. doi: 10.1186/s40478-023-01695-7. Acta Neuropathol Commun. 2024. PMID: 38581034 Free PMC article.
REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
Picca A, Touat M, Belin L, Gourmelon C, Harlay V, Cuzzubbo S, Cohen-Jonathan Moyal E, Bronnimann C, Di Stefano AL, Laurent I, Lerond J, Carpentier C, Bielle F, Ducray F, Dehais C; POLA Network. Picca A, et al. Among authors: bielle f. Eur J Cancer. 2024 May;202:114034. doi: 10.1016/j.ejca.2024.114034. Epub 2024 Mar 22. Eur J Cancer. 2024. PMID: 38537315 Clinical Trial.
Integrated proteogenomic characterization of glioblastoma evolution.
Kim KH, Migliozzi S, Koo H, Hong JH, Park SM, Kim S, Kwon HJ, Ha S, Garofano L, Oh YT, D'Angelo F, Kim CI, Kim S, Lee JY, Kim J, Hong J, Jang EH, Mathon B, Di Stefano AL, Bielle F, Laurenge A, Nesvizhskii AI, Hur EM, Yin J, Shi B, Kim Y, Moon KS, Kwon JT, Lee SH, Lee SH, Gwak HS, Lasorella A, Yoo H, Sanson M, Sa JK, Park CK, Nam DH, Iavarone A, Park JB. Kim KH, et al. Among authors: bielle f. Cancer Cell. 2024 Mar 11;42(3):358-377.e8. doi: 10.1016/j.ccell.2023.12.015. Epub 2024 Jan 11. Cancer Cell. 2024. PMID: 38215747
Brain metastasis of a urothelial neuroendocrine carcinoma: A double pitfall for neuropathologists and DNA-methylation profiling.
Tauziède-Espariat A, Masliah-Planchon J, Tran S, Filser M, Saffroy R, Bochaton D, Hasty L, Senova S, Kauv P, Mokhtari K, Adam C, Poté N, Chrétien F, Métais A, Varlet P, Bielle F, Laurenge A. Tauziède-Espariat A, et al. Among authors: bielle f. Neuropathol Appl Neurobiol. 2024 Feb;50(1):e12951. doi: 10.1111/nan.12951. Neuropathol Appl Neurobiol. 2024. PMID: 38124282 No abstract available.
Two novel tumours with NTRK2 fusion in the methylation class of extraventricular neurocytomas, including one intraventricular.
Uro-Coste E, Tauziede-Espariat A, Dubucs C, Chiforeanu DC, Siegfried A, Nicaise Y, Bauchet L, Riffaud L, Bielle F, Vasiljevic A, Appay R, Evrard S, Varlet P, Rigau V; Biopathology RENOCLIP‐LOC network. Uro-Coste E, et al. Among authors: bielle f. Brain Pathol. 2024 May;34(3):e13223. doi: 10.1111/bpa.13223. Epub 2023 Nov 23. Brain Pathol. 2024. PMID: 37994695 Free PMC article.
Hippocampal and neocortical BRAF mutant non-expansive lesions in focal epilepsies.
Lerond J, Mathon B, Scopin M, Nichelli L, Guégan J, Bertholle C, Izac B, Andrieu M, Gareau T, Donneger F, Mohand Oumoussa B, Letourneur F, Tran S, Bertrand M, Le Roux I, Touat M, Dupont S, Poncer JC, Navarro V, Bielle F. Lerond J, et al. Among authors: bielle f. Neuropathol Appl Neurobiol. 2023 Oct;49(5):e12937. doi: 10.1111/nan.12937. Neuropathol Appl Neurobiol. 2023. PMID: 37740653
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Ntafoulis I, Kleijn A, Ju J, Jimenez-Cowell K, Fabro F, Klein M, Chi Yen RT, Balvers RK, Li Y, Stubbs AP, Kers TV, Kros JM, Lawler SE, Beerepoot LV, Kremer A, Idbaih A, Verreault M, Byrne AT, O'Farrell AC, Connor K, Biswas A, Salvucci M, Prehn JHM, Lambrechts D, Dilcan G, Lodi F, Arijs I, van den Bent MJ, Dirven CMF, Leenstra S; GLIOTRAIN consortium; Lamfers MLM. Ntafoulis I, et al. Br J Cancer. 2023 Oct;129(8):1327-1338. doi: 10.1038/s41416-023-02402-y. Epub 2023 Aug 24. Br J Cancer. 2023. PMID: 37620410 Free PMC article.
A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutant.
Tran S, Thomas A, Aliouat I, Karachi C, Lozano F, Mokhtari K, Dehais C, Feuvret L, Carpentier C, Giry M, Doukani A, Lerond J, Marie Y, Sanson M, Idbaih A, Carpentier A, Hoang-Xuan K, Touat M, Capelle L, Bielle F. Tran S, et al. Among authors: bielle f. Neuropathol Appl Neurobiol. 2023 Aug;49(4):e12928. doi: 10.1111/nan.12928. Neuropathol Appl Neurobiol. 2023. PMID: 37503540
130 results